Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

trialsTrialRecruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

A phase 2 trial of Venetoclax in acute myeloid leukaemia, run by Ryvu Therapeutics SA, now recruiting.

Also called: RIVER-81

Overview Connected6

Overview

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML is a phase 2 interventional study registered as NCT06191263 by Ryvu Therapeutics SA, with 98 participants planned, started 2024-01-05 and due to reach its primary completion in 2027-08. Interventions recorded: RVU120 and Venetoclax.

Setting

A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent

Phase

Phase 2

Sponsor

Ryvu Therapeutics SA

Registry

Started

2024-01-05

Enrolled

98 enrolled

Connected

Similar pages

Trial
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Trial
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Trial
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Trial
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Trial
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Trial
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Trial
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Trial
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.

cancers

Acute myeloid leukaemia

technologies

BCL-2 inhibitors Small-molecule kinase inhibitors

drugs

Phase 2Small-molecule inhibitor

ApprovedSmall-molecule BCL-2 inhibitor

Venetoclax · Venclexta

companies

Ryvu Therapeutics

Evidence strength30/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
98 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT06191263

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Acute myeloid leukaemia

Technologies

BCL-2 inhibitors
Small-molecule kinase inhibitors

Products

Venetoclax
RVU120

Companies

Ryvu Therapeutics

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06191263/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06191263.

WebMCP tools registered on this page: onco_search, onco_get_entity.